DOI: 10.1002/joa3.12327

LETTER TO THE EDITOR

Journal of Arrhythmia WILEY

Reply "Role of antibiotic envelopes in preventing cardiac implantable electronic device infection: A meta-analysis of 14 859 procedures"

Sir,

We would like to thank Asbeutah, AAA for his interest in our manuscript and meaningful insight.^{1,2} However even following exclusion of the study by Kay et al from the meta-analysis (as the study did not report any true infections and the numbers reported were from a predictive model, combining results from other studies) the results and conclusion did not differ.³ Antibiotic envelope reduced the risk of cardiac implantable electronic device infections (RR: 0.51, Cl: 0.37-0.69, P < .05, $l^2 = 66\%$, $\chi^2 P < .05$) (Figure 1). Further as rightly pointed out, the absorbable envelope group of Kolek et al was not included in the analysis due to the overlap of subjects in the control group.⁴ This was to avoid the error of "double counting."⁵

Ashish Kumar MBBS¹ D Rajkumar Doshi MD, MPH² Mariam Shariff MBBS¹ D

¹Resident, Department of Critical Care Medicine, St John's Medical College Hospital, Bangalore, India
²Department of Internal Medicine, University of Nevada Reno School of Medicine, Reno, NV, USA

Correspondence

Ashish Kumar, Department of Critical Care Medicine, St John's Medical College Hospital, Kormangala, Bangalore 560034, India. Email: drashishkumar.u@gmail.com

CONFLICT OF INTEREST

Authors declare no conflict of interests for this article.

Antibiotic envelope Risk ratio No antibiotic envelope Risk ratio Study or subgroup Events Total Weight (%) M-H, Fixed, 95% CI Year M-H, Fixed, 95% CI Total Events 1.1.1 Non-absorbable envelope Mittal et al. 2014 3 275 10 275 8.0 0.30 [0.08, 1.08] 2014 Kolek et al.2015 353 20 636 11.5 0.09 [0.01, 0.67] 2015 1 1111 Shariff et al.2015 0 365 19 7.8 0.08 [0.00, 1.29] 2015 0.20 [0.07, 0.58] 2015 Henrikson 2017 5 1129 10 451 11.5 5.00 [0.60, 41.97] Hassoun et al. 2017 5 92 92 0.8 2017 1 Subtotal (95% CI) 2214 2565 39.6 0.26 [0.14, 0.49] Total events 14 60 Heterogeneity: Chi² = 9.48, df = 4 (P = .05); l² = 58% Test for overall effect: Z = 4.19 (P < .0001) 1.1.2 Absorbable envelope WRAP-IT 2019 50 3495 60.4 0.67 [0.47, 0.95] 2019 75 3488 3495 0.67 [0.47, 0.95] Subtotal (95% CI) 3488 60.475 Total events 50 Heterogeneity: Not applicable Test for overall effect: Z = 2.25 (P = .02) 5709 Total (95% CI) 6053 100.0 0.51 [0.37, 0.69] Total events 64 135 Heterogeneity: Chi² = 14.86, df = 5 (P = 0.01); l² = 66% 0.01 0'1 10 100 Test for overall effect: Z = 4.40 (P < .0001) Antibiotic envelope No envelope Test for subgroup differences: Chi² = 6.44, df = 1 (P = .01), I² = 84.5%

FIGURE 1 Forest plot for risk of infection (major/minor)

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2020 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society.

Ashish Kumar bhttps://orcid.org/0000-0003-4249-0055 Mariam Shariff bhttps://orcid.org/0000-0001-8799-9678

REFERENCES

- Asbeutah AAA. Role of antibiotic envelopes in preventing cardiac implantable electronic device infection: a meta-analysis of 14 859 procedures. J Arrhythmia. 2020;36(2):377.
- 2. Kumar A, Doshi R, Shariff M. Role of antibiotic envelopes in preventing cardiac implantable electronic device infection: a meta-analysis of 14 859 procedures. J Arrhythmia. 2019;36:176–9.
- Kay G, Eby EL, Brown B, Lyon J, Eggington S, Kumar G, et al. Costeffectiveness of TYRX absorbable antibacterial envelope for prevention of cardiovascular implantable electronic device infection. J Med Econ. 2018;21(3):294–300.
- Kolek MJ, Patel NJ, Clair WK, Whalen SP, Rottman JN, Kanagasundram A, et al. Efficacy of a bio-absorbable antibacterial envelope to prevent cardiac implantable electronic device infections in high-risk subjects. J Cardiovasc Electrophysiol. 2015;26(10):1111–6.
- 5. Kumar A, Shariff M, Doshi R. Alprostadil and contrast-induced nephropathy. Angiology. 2019;71(1):96.